Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1994-10-26
1997-08-19
Rories, Charles C. P.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 245, 4351723, 435 6, 435375, A61K 3170, C07H 2100, C12N 510, C12Q 168
Patent
active
056588917
ABSTRACT:
Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a gene corresponding to one of the open reading frames UL5, UL8, UL9, UL13, UL29, UL30, UL39, UL40, UL42 AND UL52 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site; it is also preferred that they comprise the sequence CAT. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide specifically hybridizable with RNA or DNA deriving from one of the foregoing genes of the herpesvirus; are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.
REFERENCES:
patent: 4689320 (1987-08-01), Kaji
patent: 5004810 (1991-04-01), Draper
T. Gura, Science, 270 (Oct. 27, 1995) 575-7.
P. Westermann et al., Biomed. Biochim. Acta 48(1)('89) 85-93.
R. Weiss, Science News 139 (Feb. 16, 1991) 108-9.
W. James, Antivirol Chem. & Chemotherapy 2(4) ('91) 191-214.
D. Grau et al., Invest. Ophthal. & Visual Sci., vol. 30, #12 (Dec. '89) pp. 2474-2480.
L. Kibler-Herzog et al., Nucl. Acids Res., vol. 19(11) ('91) pp. 2979-2986.
P. Eder et al., Antisense Res. & Dev., vol. 1 (1991) pp. 141-151.
E. Uhlmann et al., vol. 90 #4 (Jan. '90) pp. 543-584--Chemical Reviews.
J. Milligan et al., J. Med. Chem., vol. 36(14) (Jul. 9, 1993) pp. 1924-1937.
B. Tseng et al., Cancer Gene Therapy, vol. 1(1) (Mar. 1994) pp. 65-71.
C. Stein et al., Science, vol. 261 (Aug. 20, 1993) pp. 1004-1012.
V. Preston et al., Virology, vol. 167 ('88) pp. 458-467.
M. Matsukura et al., PNAS, vol. 86 ('89) pp. 4244-4248.
E. Kern, Antiviral Agents and Viral Disease in Man, 3rd Ed., edited by G. Galasso, R. Whitley, T. Merigan, 1990, Raven Press Ltd., N.Y., pp. 87 and 99.
C. Brandt et al., J. Virological Methods, 36:209-222 ('92).
Krol et al, Biotechniques 6:958-976 (1988) "Modulation of eukaryotic Gene expression . . . ".
D.J. McGeoch et al., The Complete DNA Sequence of the Long Uinque Region in the Genome of Herpes Simplex Virus Type 1, J. Gen. Virol. 69:1531-1574 (1988).
D.J. McGeoch et al., Sequence Determination and Genetic Content of the Short Unique Region in the Genome of Herpes Simplex Virus Type 1, J. Mol. Biol., 181:1-13 (1985).
D.J. McGeoch et al., Complete DNA sequence of the short repeat region in the genome of herpes simplx virus type 1, Nucleic Acids Res., 14:1727-1745 (1986).
L.J. Perry et al., The DNA Sequences of the Long Repeat Region and Adjoining Parts of the Long Unique Region in the Genome of Herpes Simplex Virus Type 1, J. Gen. Virol., 69:2831-2846 (1988).
E.D. Blair et al., Herpes Simplex Virion Stimulatory Protein mRNA Leader Contains Sequence Elements Which Increase Both Virus-induced Transcription and mRNA Stability, J. Virol., 61:2499-2508 (1987).
M. Ceruzzi et al., The Intracellular and Extracellular Fate of Oligodeoxyribonucleotides in Tissue Culter Systems, Nucleosides and Nucleotides, 8:815-818 (1989).
M.C. Frame et al., The Ribonucelotide reductase Induced by Herpes Simplex Virus Type 1 Involves Minimally a Complex of Two Polypeptides (136K and 38K), J. Gen. Virol., 66:1581-1587 (1985).
Cheng et al., Abstract & Poster Pres. at Oligonucleotides as Antisense Inhibitors of Gene Expression: Therapeutic Implications, Rockville, MD.
M. Matsukura et al., Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors of replication and cytopathic effects of human immunodeficiency virus, Proc. Natl. Acad. Sci. USA, 84:7706-7710 (1987).
M. Kulka et al., Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splic junction of herpes simplex virus type 1 immediate early mRNA 4, Proc. Natl. Acad. Sci. USA, 86:6868-6872 (1989).
C. Smith et al., Antiviral effect of an oligo(nucleoside methylphosphonate)s complementary to the splice junction of herpes simplex virus type 1 immediate early pre-mRNAs 4 and 5, Proc. Natl. Acad. Sci., USA, 83:2787-2792 (1986).
A. Davison et al., The Complete DNA Sequence of Varicella-Zoster Virus, J. Gen. Virol., 67:1759-1816 (1987).
T. Kouzarides et al., Sequence and Transcription Analysis of the Human Cytomegalovirus DNA Polymerase Gene, J. Virol., 61:125-133 (1987).
R. Baer et al., DNA Sequence and Expression of the B95-8 Epstein-Barr Virus Genome, Nature, 310:207-211 (1984).
G. Lawrence, Human Herpesvirus 6 is Closely Related to Human Cytomegalovirus, J. Virol., 64:287-299 (1989).
Crooke Stanley T.
Draper Kenneth G.
Ecker David J.
Mirabelli Christopher K.
ISIS Pharmaceuticals Inc.
Rories Charles C. P.
LandOfFree
Oligonucleotide therapies for modulating the effects of herpesvi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligonucleotide therapies for modulating the effects of herpesvi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide therapies for modulating the effects of herpesvi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1104860